Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date14 Feb 2020 |
/ Not yet recruitingPhase 4IIT A randomized, double-blind, parallel-group, multicenter clinical study to evaluate the efficacy and safety of Honghua Ruyi Wan in treatment of Pelvic inflammatory disease sequelae caused by chronic pelvic pain (qi stagnation and blood stasis syndrome)
100 Clinical Results associated with 甘南佛阁藏药有限公司
0 Patents (Medical) associated with 甘南佛阁藏药有限公司
100 Deals associated with 甘南佛阁藏药有限公司
100 Translational Medicine associated with 甘南佛阁藏药有限公司